|
gptkbp:instance_of
|
gptkb:vaccine
|
|
gptkbp:approves
|
December 2020
|
|
gptkbp:clinical_trial
|
gptkb:Argentina
gptkb:Brazil
gptkb:Germany
gptkb:Turkey
gptkb:United_States
Phase 3
|
|
gptkbp:developed_by
|
gptkb:Pfizer
gptkb:Bio_NTech
|
|
gptkbp:dosage_form
|
yes
two doses
|
|
gptkbp:emergency_services
|
granted
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
BNT162c2
|
|
gptkbp:is_effective_against
|
95% effective
|
|
gptkbp:is_vulnerable_to
|
gptkb:Comirnaty
global
ongoing
safety monitoring
varies by country
widely available
lipid nanoparticle
preventive vaccine
reduced severe disease
increased immunity
reduced transmission
reduced hospitalization
efficacy monitoring
limited in early stages
|
|
gptkbp:mechanism_of_action
|
induces immune response
|
|
gptkbp:regulatory_compliance
|
gptkb:FDA
gptkb:WHO
gptkb:EMA
|
|
gptkbp:route_of_administration
|
intramuscular
|
|
gptkbp:side_effect
|
fatigue
headache
muscle pain
fever
joint pain
chills
|
|
gptkbp:storage
|
-70° C
|
|
gptkbp:target_audience
|
gptkb:children
adults
adolescents
|
|
gptkbp:target_cell
|
human cells
|
|
gptkbp:targets
|
gptkb:COVID-19
|
|
gptkbp:type
|
gptkb:vaccine
|
|
gptkbp:vaccine_efficacy_duration
|
6 months
|
|
gptkbp:vaccine_partnership
|
gptkb:Pfizer-Bio_NTech
|
|
gptkbp:bfsParent
|
gptkb:Bio_NTech
|
|
gptkbp:bfsLayer
|
5
|